Dose-Defining Study of a NAT2 Phenotype-Based Dosing Regimen of Intravenous Amonafide L-Malate Administered Weekly in Men With Androgen-Independent Prostate Cancer (AIPC)
This is an open-label, Phase I/II, multicenter study of Amonafide in subjects with
androgen-independent metastatic prostate cancer.
Amonafide is metabolized by N-acetylation to an active metabolite, N-acetyl-Amonafide.
Inter-subject differences in N-acetylation can explain the variability in Amonafide-induced
myelosuppression. This dose-defining protocol has been designed to assess safety and
efficacy of Amonafide in men with androgen-independent prostate cancer, assigned to
individualized doses based on acetylator phenotype information.
The total duration of this study will be approximately 12 - 16 months: approximately 6 - 10
months for enrollment, and approximately 6 months for subject screening, treatment, and
follow up per protocol. Subjects will be treated until PSA progression, disease
progression, or unacceptable toxicity.
Subjects may continue participation in the study after Cycle 5 at the investigator's
discretion if PSA progression, disease progression, or unacceptable toxicities are not
reported. If a subject fulfills a criterion of PSA progression or disease progression, yet
in the opinion of the investigator, the subject appears to be deriving clinical benefit from
the study medication, a request may be made to the Xanthus medical monitor to allow that
subject to continue study participation on a compassionate basis.
A follow-up evaluation for all subjects will be done 30 - 35 days after receiving the last
dose of Amonafide. Subjects will be contacted every 3 months for survival after completion
of the active phase of the study, until death.
PSA response will be reported for all subjects receiving Amonafide treatment. PSA levels
will be measured at Screening and once per treatment cycle thereafter (at Day 1 of each
cycle). A PSA responder will be defined as a subject experiencing a 50% decrease in PSA
level, confirmed four or more weeks later, with no demonstration of clinical or radiographic
evidence of disease progression prior to the second PSA measurement. Duration PSA response
and time to PSA progression will also be reported.
In addition to PSA endpoints, traditional response criteria such as overall tumor response
rate (complete + partial tumor response), duration of tumor response, and time to tumor
progression will be captured for all subjects with measurable lesions. All complete and
partial responses must be confirmed by repeat assessments that should be performed no less
than 4 weeks after the criteria for response are met.
Subsequently, in order to evaluate safety, all subjects will be assessed for signs of
adverse events according to the Common Terminology Criteria for Adverse Events (CTCAE)
version 3 dated June 10, 2003.
All serious adverse events (SAEs) and grade ¾ toxicities will be reviewed by the Sponsor's
medical monitor. Appropriate action may be taken to terminate or put the study on hold if
warranted by unanticipated toxicity.
Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
The Primary Objectives of this study are:
Michel Drouin, MD
Xanthus Life Sciences-Medical Monitor
United States: Food and Drug Administration
|Fox Chase Cancer Center||Philadelphia, Pennsylvania 19111|
|Cancer Institute of New Jersey||New Brunswick, New Jersey 08901|
|Seattle Cancer Care Alliance||Seattle, Washington 98109|
|USC Norris Comprehensive Cancer Center||Los Angeles, California 90089|
|The Cleveland Clinic||Cleveland, Ohio 44195|
|Cancer Center at John Hopkins||Baltimore, Maryland 21231|
|Barnard Cancer Center||St.Louis, Missouri 63110|
|Herbert Irving Cancer Center||New York, New York 10032-3789|